# David Woodhouse

> David J. Woodhouse is a scientist, former biotechnology investment banker, and company builder who became chief executive of Nuvig Therapeutics in September 2025. His career crosses research at Amgen and Dynavax, 13 years at Goldman Sachs, and a decade at NGM Biopharmaceuticals, where he moved from CFO to CEO, led the company into the public markets, and later helped return it to private ownership. At Nuvig, he is applying that combined scientific, financial, and operating perspective to a clinical-stage platform at a moment when capital discipline and development judgment matter as much as a compelling laboratory idea.

- **Role:** Chief Executive Officer and Board Director at Nuvig Therapeutics
- **Organizations:** Nuvig Therapeutics, Surrozen, NGM Biopharmaceuticals, Goldman Sachs, Dynavax Technologies, Amgen
- **Education:** B.A. in Pharmacology, highest honors, University of California, Santa Barbara, Ph.D. in Molecular Pharmacology, Stanford University School of Medicine, M.B.A., Tuck School of Business at Dartmouth
- **Known for:** Advised biotechnology, specialty pharmaceutical, and diagnostics companies on several billion dollars of equity and equity-linked financings and more than $90 billion of M&A transactions while at Goldman Sachs., Advanced from CFO to CEO at NGM Biopharmaceuticals and led its transition into the public markets in 2019., Led NGM during an IPO and concurrent Merck private placement that generated $173.7 million in net proceeds.

## Career timeline

- **Early career** — Worked as a research assistant at Amgen and later in research and business development roles at Dynavax Technologies.
- **2002-2015** — Worked at Goldman Sachs, ultimately becoming a managing director and co-head of U.S. biotechnology investment banking.
- **2015** — Joined NGM Biopharmaceuticals as chief financial officer.
- **2018** — Appointed chief executive officer and elected to NGM Biopharmaceuticals' board.
- **2019** — Led NGM as it began trading on Nasdaq; the IPO and concurrent Merck placement produced $173.7 million in net proceeds.
- **2020** — Joined the board of Surrozen.
- **2023** — Became chair of Surrozen's board.
- **2024** — Led NGM through its return to private ownership in a transaction with affiliates of The Column Group; NGM subsequently announced a $122 million private financing.
- **2025** — Appointed chief executive officer and board director of Nuvig Therapeutics on September 9.

## Achievements

- Advised biotechnology, specialty pharmaceutical, and diagnostics companies on several billion dollars of equity and equity-linked financings and more than $90 billion of M&A transactions while at Goldman Sachs.
- Advanced from CFO to CEO at NGM Biopharmaceuticals and led its transition into the public markets in 2019.
- Led NGM during an IPO and concurrent Merck private placement that generated $173.7 million in net proceeds.
- Guided NGM through multiple clinical milestones and strategic partnerships during a decade with the company.
- Serves as chair of Surrozen's board, after joining it in September 2020 and becoming chair in April 2023.
- Was selected in 2025 to lead Nuvig Therapeutics as it advanced a clinical-stage program and broadened its platform.

## Latest updates

- **2025-12** — Participated in a Fierce Pharma panel on disciplined financing, early evidence planning, external partnerships, culture, and decision rules in biotech.
- **2025-09** — Joined Nuvig Therapeutics as chief executive officer and a member of its board of directors.
- **2025-09** — Marked Nuvig's inclusion in the 2025 Fierce 15 and reiterated his focus on advancing the company's lead program and platform.

## Links

- Website: https://nuvigtx.com
- LinkedIn: https://www.linkedin.com/in/david-woodhouse-860b448
- Twitter/X: https://twitter.com/nuvigtx

---

Profile page: https://yespress.io/david-woodhouse
Published by YesPress — https://yespress.io
Last updated: 2026-08-18